Biotech company Biosergen has had such good results with the first four groups of subjects in their Phase 1 study that they are now launching the next part of the study, which involves “multiple dose” as opposed to “single dose” so far in the study. This is a quarter ahead of schedule and supports the investment case of Biosergen and the SEK 60M rights issue.
Biosergen: Ticker BIOSGN | Price: 4,1 | Market Cap.: SEK 115M | YTD price development: -23%
Biosergen is a biotech company listed on Nasdaq First North Sweden in June 2021. The company is developing an innovative drug to treat fungal infections that kill 1.5 million people annually – in both industrialised and third world countries.
The company’s BSG005 agent has demonstrated significant safety data and potency advantages over existing products developed in the 1950s-70s. BSG005 is in clinical phase I (the first of three phases of development towards the market), from which positive data have emerged. The first of several drugs is expected to be on the market in 2026/27.
No harmful effect on liver or kidneys
One of the two major benefits of Bioserg’s treatment for aggressive (deadly) fungal infections is that patients do not suffer kidney damage, a major side effect of existing treatment. Preliminary results of the Phase 1 study have shown that subjects have not experienced any liver or kidney side effects, so the multiple dose part of the study is already underway.